Related Experiment Video
Updated: Jun 28, 2026
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials
Abstract:
The current high cure rates for children diagnosed with cancer can be attributed in part to emphasis on large cooperative group clinical trials. The significant improvement in pediatric cancer survival over the past few decades is the result of optimized chemotherapy drug dosing, timing, and intensity; however, further alterations in traditional chemotherapy agents are unlikely to produce substantially better outcomes. Furthermore, there remains a subset of patients who have a very poor prognosis due to tumor type or stage at presentation, or who have a dismal prognosis with relapse or recurrence. As such, innovative approaches to therapy and new drugs are clearly needed for introduction into the current pediatric oncology arsenal. A variety of biologically targeted therapies that have shown promise in preclinical studies and early-phase adult clinical trials are now being explored in pediatric clinical trials. These novel agents hold the promise for continuing to drive forward improvements in patient survival, with potentially less toxicity than exists with traditional chemotherapy drugs.
Insights
Pediatric cancer survival has improved due to clinical trials and chemotherapy optimization. New targeted therapies are now being explored to further enhance outcomes and reduce toxicity for children with difficult-to-treat cancers.
Area of Science:
- Pediatric Oncology
- Cancer Therapeutics
- Clinical Trials
Background:
- High cure rates in pediatric cancer are partly due to cooperative group clinical trials.
- Optimized chemotherapy has significantly improved survival, but further gains are limited.
- A subset of pediatric cancer patients still faces poor prognoses due to tumor type, stage, or recurrence.
Purpose of the Study:
- To highlight the need for innovative therapeutic approaches in pediatric oncology.
- To introduce the exploration of novel, biologically targeted therapies in pediatric clinical trials.
- To address the limitations of traditional chemotherapy in improving outcomes for all children with cancer.
Main Methods:
- Review of current pediatric cancer treatment strategies.
- Exploration of biologically targeted therapies showing promise in preclinical and adult trials.
- Initiation of pediatric clinical trials for novel therapeutic agents.
Main Results:
- Biologically targeted therapies are being investigated in pediatric clinical trials.
- These novel agents have shown promise in preclinical studies and early adult trials.
- Potential for improved patient survival and reduced toxicity compared to traditional chemotherapy.
Conclusions:
- Innovative therapies are crucial for advancing pediatric cancer treatment.
- Biologically targeted agents offer a promising new avenue for improving survival rates.
- Future research should focus on integrating these novel therapies to overcome treatment resistance and reduce side effects.
Related Concept Videos
01:11Clinical Trials: Overview
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:28Preclinical Development: Overview
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...